The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

So having a representative population is really important. One part of that is being able to enroll more patients in the ...

In today’s ACT Brief, we examine persistent barriers limiting cancer trial participation and emerging approaches to address ...

Understand which barriers to cancer trial participation remain most difficult to overcome, including geography and trial ...

By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, ...

In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...

Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...

Examine how the American Cancer Society’s national ACTS expansion is designed to simplify trial discovery, reduce logistical ...

A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...

In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...